These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 17548170)

  • 1. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.
    Tsai SJ
    Med Hypotheses; 2007; 69(6):1219-21. PubMed ID: 17548170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glatiramer acetate could be a potential antidepressant through its neuroprotective and anti-inflammatory effects.
    Tsai SJ
    Med Hypotheses; 2007; 69(1):145-8. PubMed ID: 17196755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease.
    Kurkowska-Jastrzebska I; Litwin T; Joniec I; Ciesielska A; Przybyłkowski A; Członkowski A; Członkowska A
    Int Immunopharmacol; 2004 Oct; 4(10-11):1307-18. PubMed ID: 15313429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ.
    Aharoni R; Kayhan B; Eilam R; Sela M; Arnon R
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14157-62. PubMed ID: 14614135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel anti-inflammatory therapy for Parkinson's disease.
    Gao HM; Liu B; Zhang W; Hong JS
    Trends Pharmacol Sci; 2003 Aug; 24(8):395-401. PubMed ID: 12915048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease.
    Fumagalli F; Racagni G; Riva MA
    Pharmacogenomics J; 2006; 6(2):95-104. PubMed ID: 16402079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glatiramer acetate: mechanisms of action in multiple sclerosis.
    Ziemssen T; Schrempf W
    Int Rev Neurobiol; 2007; 79():537-70. PubMed ID: 17531858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
    Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
    Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson's disease.
    Whitton PS
    Curr Opin Investig Drugs; 2010 Jul; 11(7):788-94. PubMed ID: 20571974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?
    Rogers J; Mastroeni D; Leonard B; Joyce J; Grover A
    Int Rev Neurobiol; 2007; 82():235-46. PubMed ID: 17678964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maturation but not survival of dopaminergic nigrostriatal neurons is affected in developing and aging BDNF-deficient mice.
    Baker SA; Stanford LE; Brown RE; Hagg T
    Brain Res; 2005 Mar; 1039(1-2):177-88. PubMed ID: 15781060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.
    Ekstrand MI; Galter D
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S185-8. PubMed ID: 20082987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
    Kim S; Moon M; Park S
    J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glatiramer acetate could be a hypothetical therapeutic agent for neuromyelitis optica.
    Wang KC; Lee CL; Chen SY; Lin KH; Tsai CP
    Med Hypotheses; 2011 Jun; 76(6):820-2. PubMed ID: 21398045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease.
    Salehi Z; Mashayekhi F
    J Clin Neurosci; 2009 Jan; 16(1):90-3. PubMed ID: 19017558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the treatment of Parkinson's disease.
    Singh N; Pillay V; Choonara YE
    Prog Neurobiol; 2007 Jan; 81(1):29-44. PubMed ID: 17258379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis and Parkinson's disease.
    Lev N; Melamed E; Offen D
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Apr; 27(2):245-50. PubMed ID: 12657363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
    Hald A; Lotharius J
    Exp Neurol; 2005 Jun; 193(2):279-90. PubMed ID: 15869932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glial reactions in Parkinson's disease.
    McGeer PL; McGeer EG
    Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.